Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study
Diabetes, Obesity and Metabolism Jul 04, 2020
Klaff L, Cao D, Dellva MA, et al. - A 26‐week, treat‐to‐target, phase 3 trial was designed to assess the effectiveness and safety of ultra rapid lispro (URLi) vs lispro in adults with type 1 diabetes. Individuals were assigned randomly to double‐blind mealtime URLi (n = 451) or lispro (n = 442), or open‐label post‐meal URLi (n = 329) after an 8‐week lead‐in to optimize basal insulin glargine or degludec, The primary outcome included change from baseline glycated haemoglobin to 26 weeks (non‐inferiority margin 0.4%), with multiplicity‐adjusted objectives for postprandial glucose (PPG) excursions after a meal test. The outcomes revealed that, while superior PPG control was illustrated with mealtime dosing, URLi provided good glycaemic control, with non‐inferiority to lispro confirmed for both mealtime and post‐meal URLi.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries